GlassScriptPhysician profile
Brielle Lavance Brown
NPI 1760817175
$8,342.45
in general payments reported to CMS, 2019-2025
65 companies · $1,522 in 2025
The $1,522 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,586 · 2022: $1,778 · 2023: $1,694 · 2024: $1,763 · 2025: $1,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,853 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,852.58 |
| Education | $125.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $660.46 | 2021-2025 | |
| Seagen INC. | $574.19 | 2021-2025 | Tukysa, Adcetris, Padcev |
| Astrazeneca Pharmaceuticals LP | $569.19 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| Amgen INC. | $526.62 | 2021-2023 | Blincyto, Vectibix, Xgeva |
| Janssen Biotech, INC. | $486.51 | 2021-2025 | Darzalex, Tecvayli, Erleada |
| Lilly USA, LLC | $356.87 | 2021-2025 | Retevmo, Jaypirca, Verzenio |
| Takeda Pharmaceuticals U.S.A., INC. | $298.74 | 2021-2024 | Alunbrig, Iclusig |
| Daiichi Sankyo INC. | $286.37 | 2021-2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $274.30 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $256.66 | 2021-2025 | Keytruda, Reblozyl, Welireg |
| Pfizer INC. | $249.63 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $244.26 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Celgene Corporation | $195.37 | 2022-2025 | Reblozyl, Opdualag, Opdivo |
| Ipsen Biopharmaceuticals, INC | $177.57 | 2022-2025 | Onivyde, Somatuline Depot |
| Eisai INC. | $175.34 | 2021-2024 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $153.62 | 2021-2025 | |
| G1 Therapeutics, INC. | $146.23 | 2022-2023 | Cosela |
| Incyte Corporation | $144.43 | 2021-2025 | Zynyz, Monjuvi, Jakafi |
| Myriad Genetic Laboratories, INC. | $141.68 | 2022-2023 | Myrisk |
| Emd Serono, INC. | $132.58 | 2022-2025 | Bavencio |
| Sobi, INC | $130.79 | 2024-2025 | |
| Glaxosmithkline, LLC. | $115.88 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Regeneron Healthcare Solutions, INC. | $107.03 | 2022-2024 | Libtayo |
| Taiho Oncology, INC. | $105.22 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $94.65 | 2022-2025 | Xpovio |
| Agios Pharmaceuticals, INC. | $93.29 | 2023-2025 | Pyrukynd |
| Pharmaessentia USA Corporation | $92.25 | 2022-2025 | Besremi |
| Gilead Sciences, INC. | $91.08 | 2023-2025 | Trodelvy |
| Abbvie INC. | $84.10 | 2021-2025 | |
| Genmab U.S., INC. | $82.73 | 2023-2025 | Epkinly |
| Astellas Pharma US INC | $81.22 | 2021-2025 | Vyloy, Padcev |
| Pharmacosmos Therapeutics INC. | $80.38 | 2024-2025 | Monoferric, Cosela |
| Array Biopharma INC | $78.30 | 2021-2023 | Braftovi, Lorbrena, Mektovi |
| Bayer Healthcare Pharmaceuticals INC. | $74.67 | 2021-2023 | |
| Blueprint Medicines Corporation | $68.21 | 2022-2023 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.98 | 2021-2023 | Gilotrif |
| Kyowa Kirin, INC. | $56.00 | 2023-2025 | Poteligeo |
| Mirati Therapeutics, INC. | $50.74 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $50.26 | 2023-2024 | Orserdu |
| Alexion Pharmaceuticals, INC. | $47.98 | 2021-2022 | |
| Csl Behring | $43.05 | 2022-2025 | Idelvion, Afstyla |
| Octapharma USA, INC. | $41.56 | 2024-2025 | Octagam Immune Globulin (Human) |
| Rigel Pharmaceuticals, INC. | $37.21 | 2023-2024 | Rezlidhia, Tavalisse |
| Genentech USA, INC. | $37.11 | 2022-2023 | Gazyva, Venclexta, Lunsumio |
| Servier Pharmaceuticals LLC | $37.02 | 2024 | |
| Adaptive Biotechnologies Corporation | $36.33 | 2024-2025 | Clonoseq |
| Exelixis INC. | $34.83 | 2021-2025 | Cabometyx |
| Morphosys, US INC. | $34.35 | 2022-2023 | Monjuvi |
| Legend Biotech USA INC. | $29.29 | 2024-2025 | Carvykti |
| Puma Biotechnology, INC. | $28.05 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $27.10 | 2021-2022 | |
| Deciphera Pharmaceuticals INC. | $25.99 | 2021 | |
| Azurity Pharmaceuticals, INC. | $24.91 | 2025 | Danziten |
| Springworks Therapeutics, INC. | $24.76 | 2025 | Ogsiveo |
| Dova Pharmaceuticals | $22.74 | 2021 | |
| Amag Pharmaceuticals, INC. | $21.38 | 2022 | |
| Heron Therapeutics, INC. | $19.74 | 2021 | |
| Adc Therapeutics America, INC. | $17.66 | 2022 | |
| Eusa Pharma (US) LLC | $17.28 | 2022 | |
| Aveo Pharmaceuticals, INC. | $15.85 | 2023 | Fotivda |
| Novocure INC. | $15.53 | 2025 | Optune Gio |
| Boston Scientific Corporation | $15.22 | 2024 | |
| Myovant Sciences INC. | $14.34 | 2021 | |
| Ge Healthcare | $13.97 | 2022 | |
| Sun Pharmaceutical Industries INC. | $13.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brielle Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.